Ewa Izabela Wojtaszek

Dr. Ewa Izabela Wojtaszek


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAleksandra Golenia
Aleksandra Golenia
POPiotr Olejnik
Piotr Olejnik
OMOliwia Maciejewska
Oliwia Maciejewska
EWEwa Izabela Wojtaszek
Ewa Izabela Wojtaszek
PŻPaweł Żebrowski
Paweł Żebrowski
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Background: Chronic kidney disease (CKD) is a risk factor for cognitive impairment (CI), and this risk is the highest in patients with end-stage kidney disease (ESKD). As a multifactorial disease, CI may be influenced by several potentially modifiable lifestyle and behavioral factors that may reduce or increase the risk of dementia. The aim of this study was to evaluate the associations between the known modifiable risk factors for dementia and the risk of CI in patients with ESKD treated with renal replacement therapy. The Charlson Comorbidity Index and the risk of CI in patients with ESKD were also assessed. Methods: In this cross-sectional study, 225 consecutive patients with ESKD treated with different modalities of renal replacement therapy were assessed for cognitive decline using the Addenbrooke’s Cognitive Examination (ACE III) test. Information was also collected on modifiable risk factors for dementia, medical history and demographics. Results: This study included 117 patients after kidney transplantation (KT) and 108 patients with ESKD undergoing peritoneal dialysis and hemodialysis. The prevalence of modifiable risk factors for dementia differed between the groups; KT patients were more likely to be physically active, residing in cities with populations of less than 500,000 inhabitants, and were less likely to suffer from depression. Furthermore, the KT group had a lower Charlson Comorbidity Index score, indicating less severe comorbidities, and a lower risk of CI (3.6 ± 1.67 vs. 5.43 ± 2.37; p = 0.001). In both the KT and dialysis groups, patients with CI were more likely to have a sedentary lifestyle (45% vs. 9%, p = 0.001 and 88% vs. 48%, p = 0.001, respectively), whereas lower educational attainment and depression had a significant negative impact on ACE III test results, but only in KT patients. Finally, cognitive function in dialysis patients was negatively affected by social isolation and living in urban areas. Conclusions: Modifiable risk factors for dementia, particularly a sedentary lifestyle, are associated with a higher risk of CI in patients treated with different renal replacement therapy modalities. As CI is an irreversible condition, it is important to identify lifestyle-related factors that may lead to dementia in order to improve or maintain cognitive function in patients with ESKD.

19 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
WMWojciech Marcinkowski
Wojciech Marcinkowski
Konrad ZuzdaKonrad Zuzda
Konrad Zuzda
JZJacek Piotr Zawierucha
Jacek Piotr Zawierucha
TPTomasz Prystacki
Tomasz Prystacki
PŻPaweł Żebrowski
Paweł Żebrowski
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Background: Patients with end-stage kidney disease undergoing hemodialysis are particularly vulnerable to severe COVID-19 as a result of older age and multimorbidities. Objectives: Data are still limited and there are no published data on mortality in hemodialyzed patients in Poland, in particular when vaccines became available. We assessed the epidemiologic and clinical data of patients with laboratory-confirmed COVID-19 and assessed the mortality in 2019, 2020, and 2021, as well as the vaccination rate in 2021. Patients and Methods: Retrospectively collected data from 73 Fresenius Nephrocare Poland hemodialysis centers and one public unit were analyzed. Results: In 2021, the vaccination rate was 96%. The unadjusted mortality (number of deaths divided by number of patients) in 2019 was 18.8%, while the unadjusted (after exclusion of COVID-related deaths) mortality in 2020 was 20.8%, and mortality in 2021 was 16.22%. The prevalence of cardiovascular deaths in 2019 and 2020 was almost identical (41.4% vs. 41.2%, respectively), and in 2021, the figures increased slightly to 44.1%. The prevalence of sudden cardiac deaths in 2019 was higher than in 2020 (19.6% vs. 17.3%, respectively) and consequently decreased in 2021 (10.0%), as well as strokes (6.2% vs. 5.4%, and 3.31% in 2021), whereas deaths due to gastrointestinal tract diseases were lower (2.5% vs. 3.2%, and 2.25% in 2021), diabetes complications (0.5% vs. 1.3%, and 0.5% in 2021), sepsis (5.1% vs. 6.3%, and 8.79% in 2021), respiratory failure (1.2 vs. 1.6%, and 2.83% in 2021), and pneumonia (1.4% vs. 2.0%, and 0.82%). There were 1493 hemodialyzed COVID-19 positive patients, and among them, 191 died in 2020 (12.79%). In 2021, there were 1224 COVID-19 positive patients and 260 died (21.24%). The mortality of COVID-19 positive dialyzed patients contributed 13.39% in 2020 and 16.21% in 2021 of all recorded deaths. Conclusions: The mortality among HD patients was higher in 2021 than in 2020 and 2019, despite the very high vaccination rate of up to 96%. The higher non-COVID-19 mortality may be due to the limited possibility of hospitalization and dedicated care during the pandemic. This information is extremely important in order to develop methods to protect this highly vulnerable patient group. Prevention plays a key role; other measures are essential in the mitigation and spread of COVID-19 in HD centers.

25 October 2025 in Journal Of Nephrology
Verified
Journal Article
Open access
PDF file
POPiotr Olejnik
Piotr Olejnik
AGAleksandra Golenia
Aleksandra Golenia
OMOliwia Maciejewska
Oliwia Maciejewska
DKDominika Kurzawa
Dominika Kurzawa
EWEwa Izabela Wojtaszek
Ewa Izabela Wojtaszek
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Background There are unexplained sex differences regarding prevalence, morbidity, and mortality in chronic kidney disease (CKD). Of note, females are less likely to be waitlisted and experience longer waiting times for kidney transplant (KTx). Recently, interest in cognitive impairment among CKD patients has increased due to its potential negative impact on therapeutic outcomes. This study aimed to investigate the influence of sex on cognitive impairment prevalence and patterns, as well as modifiable dementia risk factors, in KTx recipients. Methods This cross-sectional study screened KTx recipients for cognitive impairment using the Mini-Addenbrooke’s Cognitive Examination. Demographic data, medical histories, and laboratory results were collected from medical records. Results The study included 126 consecutive KTx recipients, predominantly male (62%). Males showed higher serum creatinine (1.57 vs. 1.25 mg/dL; p = 0.001), urea (59.50 vs. 55.00 mg/dL; p = 0.046), and uric acid (7.20 vs. 6.20 mg/dL; p = 0.012) levels compared to females. However, creatinine clearance rates did not differ significantly between sexes (49.03 ± 20.29 vs. 50.79 ± 21.7 mL/min/1.73 m2; p = 0.645). A non-significant trend toward higher smoking prevalence among males was observed (p = 0.054). Cognitive impairment prevalence in the overall cohort was 23%, with no significant sex difference (males: 23.1%, females: 22.9%). Conclusions There was a high prevalence of cognitive impairment among KTx recipients, affecting both sexes equally. Male predominance in the study cohort likely reflects systemic disparities in transplant access. These findings highlight the importance of integrating sex-specific considerations into the management and follow-up care of KTx recipients. Graphical abstract

Verified
Journal Article
Open access
PDF file
Letycja RógLetycja Róg
Letycja Róg
MPMichał Marcin Pyrża
Michał Marcin Pyrża
EWEwa Izabela Wojtaszek
Ewa Izabela Wojtaszek
TGTomasz Głogowski
Tomasz Głogowski
AKAleksandra Kaszyńska
Aleksandra Kaszyńska
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Background: Renal cell carcinoma (RCC) accounts for nearly 90% of kidney cancers. Transplantation is the best treatment for kidney failure, associated with improved survival, quality of life, and lower societal costs compared with remaining on dialysis. Thanks to modern immunosuppression, rejection rates have decreased. Cancer is the second most common cause of morbidity and mortality in kidney transplant recipients (KTRs) after cardiovascular disease. KTRs are at increased cancer risk due to chronic immunosuppression. Case report: We report a 54-year-old kidney transplant recipient without prior history of malignancy who developed metachronous bilateral RCC early posttransplant (first RCC within 3 months after kidney transplantation and second RCC after one year later). Both tumours were treated with nephrectomy. Conclusions: Early diagnosis enabled appropriate oncologic management while preserving graft function. It should also be stressed that beside graft assessment, abdominal sonography should not be forgotten in kidney allograft recipients, in particular, in certain high-risk patients (i.e., elderly, male, with longer dialysis vintage, smokers, obese, with high burden of immunosuppression including pretransplant immunosuppressive therapy, induction at transplantation, etc.).